Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically proven breast cancer, eligible for neoadjuvant or adjuvant myelosuppressive chemotherapy~2. Women ≥ 18 years of age~3. Estimated life expectancy of more than six months~Exclusion Criteria:~1. Previous or concurrent malignancy except non-invasive non-melanoma skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least ten years prior to study entry~2. Any serious illness or medical condition that may interfere with safety, compliance, response to the products under investigation and their evaluation, e.g.:~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EP2006 (Type: EXPERIMENTAL): Eligible patients will be teated with EP2006
- Filgrastim (Type: ACTIVE_COMPARATOR): Eligible patients will be teated with Filgrastim

Based on this trial design, predict the completion outcome and termination type (if applicable).